Today: 21 May 2026
Browse Category

NYSE:MRK 21 January 2026 - 4 February 2026

Merck stock price rises after hours after choppy day — MRK traders focus on 2026 outlook and FDA dates

Merck stock price rises after hours after choppy day — MRK traders focus on 2026 outlook and FDA dates

Merck shares rose 2.2% in after-hours trading Tuesday, closing at $115.84 after the company’s 2026 revenue forecast missed Wall Street estimates. The drugmaker cited a $2.5 billion hit from patent expirations, Medicare price talks, and weaker COVID-19 pill sales. Investors are watching Keytruda demand, Gardasil’s China performance, and FDA decisions expected later in 2026.
4 February 2026
··
Dow Jones slips 167 points on AI disruption fears; Alphabet, Amazon earnings next

Dow Jones slips 167 points on AI disruption fears; Alphabet, Amazon earnings next

The Dow Jones Industrial Average fell 166.67 points, or 0.34%, to 49,240.99 Tuesday as tech and software stocks dropped on AI disruption fears. IBM and Salesforce weighed heavily, while Walmart rose 3% to surpass a $1 trillion market cap. The S&P 500 lost 0.84% and the Nasdaq slid 1.43%. Earnings from Alphabet and Amazon are due next.
3 February 2026
···········
Merck stock rises despite cautious 2026 outlook as patent losses loom

Merck stock rises despite cautious 2026 outlook as patent losses loom

Merck shares rose 3.1% to $116.86 after fourth-quarter earnings beat estimates, with Keytruda sales up 7% to $8.37 billion. The company forecast 2026 sales of $65.5–$67.0 billion, below Wall Street expectations, citing patent expirations and pricing pressure. Gardasil sales fell 34% to $1.03 billion. The FDA accepted Merck’s application for Winrevair, with a decision expected by September 2026.
3 February 2026
··
Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

The Health Care Select Sector SPDR Fund (XLV) rose 0.6% to $154.74 Friday, while the S&P 500 fell 0.43%. Healthcare and consumer staples were the only S&P sectors in positive territory as investors shifted to defensive stocks. Major managed-care shares lagged after a minimal proposed Medicare Advantage rate hike. Pfizer, Merck, and Eli Lilly report earnings next week.
1 February 2026
·····
Merck stock jumps to $110 as MRK heads into a big earnings week

Merck stock jumps to $110 as MRK heads into a big earnings week

Merck shares rose 1.8% to $110.27 Friday, outperforming a falling S&P 500 and closing about 2% below their 52-week high. Trading volume topped 19 million shares, well above rivals. Investors await Merck’s Feb. 3 earnings call and new inflation data that could affect rate expectations. Markets reacted to President Trump’s Fed pick and mixed inflation signals.
31 January 2026
···
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck shares rose 1.2% to $109.64 Friday afternoon, outperforming a falling S&P 500. Health care stocks attracted buyers as inflation data came in hotter than expected and Donald Trump named Kevin Warsh as Federal Reserve chair. Investors are watching for Merck’s Feb. 3 earnings call, with focus on 2026 guidance and Keytruda sales trends.
30 January 2026
···
Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna shares fell 6.09% to $48.71 Friday after CEO Stéphane Bancel said the company will scale back new late-stage vaccine trials, citing U.S. resistance and policy delays. The drop followed a midweek rally on positive cancer vaccine data with Merck. Investors await Moderna’s Feb. 13 results for further updates. U.S. markets are closed until Monday.
24 January 2026
···
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·····
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares fell 1.9% to $25.62 Friday as the stock went ex-dividend, nearly matching the $0.43 payout. The drop outpaced the health-care sector, with Moderna tumbling over 7% and Merck down 1%. Policy changes under Health Secretary Robert F. Kennedy Jr. have unsettled vaccine makers. Pfizer reports quarterly results and hosts a webcast on Feb. 3.
23 January 2026
·····
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna shares rose 7.7% to $53.65 Thursday after five-year data showed its personalized cancer vaccine with Merck’s Keytruda cut melanoma recurrence or death risk by 49%. The phase 2b trial enrolled 157 patients and met its primary endpoint. Investors await phase 3 trial updates and Moderna’s Feb. 13 results call. The stock had jumped 15.8% Wednesday on the initial data release.
22 January 2026
··
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna shares held steady at $49.81 premarket Thursday after surging 15.8% on five-year melanoma data for its cancer vaccine with Merck. The vaccine-Keytruda combo cut recurrence or death risk by 49% versus Keytruda alone. U.S. vaccine-policy uncertainty is adding risk for the sector. Investors await Moderna’s Feb. 13 earnings call for updates on oncology data and 2026 sales.
22 January 2026
··
Dow Jones rebounds as Trump rules out force on Greenland; tariffs still hang over Wall Street

Dow Jones rebounds as Trump rules out force on Greenland; tariffs still hang over Wall Street

The Dow Jones rose about 0.6% Wednesday, recovering nearly 297 points after President Trump ruled out using force to acquire Greenland. Tuesday saw the index plunge 870 points following new U.S. tariffs on European goods. Merck and UnitedHealth led early gains, while IBM and 3M dragged on the previous session. Investors await jobless claims data Thursday and the Fed meeting next week.
21 January 2026
······
Dow Jones rebounds after Tuesday’s 870-point hit as Trump cools Greenland talk

Dow Jones rebounds after Tuesday’s 870-point hit as Trump cools Greenland talk

The Dow Jones rose 203 points to 48,692.15 early Wednesday, rebounding after Tuesday’s 870-point drop triggered by Trump’s tariff threats on eight European countries. Healthcare stocks led gains, with Merck and UnitedHealth adding about 40 points. The Supreme Court began hearing arguments on Trump’s bid to fire Fed Governor Lisa Cook. A Reuters poll showed economists expect the Fed to hold rates steady this quarter.
21 January 2026
·······
1 2 3 4 … 8

Stock Market Today

  • IonQ Soars 755% Revenue Growth, Expands into Satellite Networking
    May 21, 2026, 7:35 AM EDT. IonQ reported a 755% year-over-year revenue increase after shifting to a full-stack quantum computing model. The firm also announced expansion into satellite networking, signaling broader applications for its technology. This growth and diversification led to a rating upgrade, positioning IonQ as a standout quantum stock with notable upside potential and distinct risks.

Latest articles

Quantum Stocks Surge on $2 Billion Play; IonQ Faces Next Hurdle

Quantum Stocks Surge on $2 Billion Play; IonQ Faces Next Hurdle

21 May 2026
IonQ shares jumped 8% in premarket trading Thursday to $52.47 after the U.S. announced $2 billion in quantum-computing grants, though IonQ was not among the recipients. The company recently reported first-quarter revenue of $64.7 million, up 755% year-over-year, and raised its 2026 revenue outlook to $260–$270 million. SkyWater shareholders approved IonQ’s merger, pending regulatory approval.
Rigetti Shares Rally on U.S. Quantum Funding as Debate Over Value Returns

Rigetti Shares Rally on U.S. Quantum Funding as Debate Over Value Returns

21 May 2026
Rigetti Computing shares jumped 13.2% in premarket trading Thursday after reports the Trump administration will award $2 billion in grants to nine quantum-computing firms, including $100 million for Rigetti. The company reported Q1 revenue of $4.4 million and an operating loss of $26 million. Shares closed Wednesday at $16.88, quoted at $19.10 before the market opened.
VIDA Global Stock Draws Attention After AI Agent IPO

VIDA Global Stock Draws Attention After AI Agent IPO

21 May 2026
VIDA Global shares jumped 81.2% to close at $4.15 Wednesday, then traded at $4.97 pre-market Thursday after volatile early sessions on NYSE American. Founder and CEO Lyle Pratt bought 187,500 shares at the $4 IPO price, SEC filings showed. The company raised $15 million in its IPO last week, selling 3.75 million shares. VIDA reported 2025 revenue of $551,383 and a net loss of $2.9 million.
Go toTop